BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

GTX-102: trial readouts and FDA decisions

0 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 3 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Ultragenyx Pharmaceutical Inc. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No trials in this window.

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-30P2Ultragenyx Pharmaceutical Inc RARENCT07157254 A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)Angelman Syndrometerminated55
2026-10-30P3Ultragenyx Pharmaceutical Inc RARENCT06415344 Long-term Extension of GTX-102 in Angelman SyndromeAngelman Syndrometerminated66
2026-07-10P3Ultragenyx Pharmaceutical Inc RARENCT06617429 Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)Angelman Syndrometerminated129

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.